Could a Weight-Loss drug stop colon cancer before it starts?
NCT ID NCT07095517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether tirzepatide, a drug used for diabetes and weight loss, can lower biological markers linked to colorectal cancer risk. Researchers will enroll 20 adults aged 18-50 with a BMI between 27 and 40 who have had a recent colonoscopy. The goal is to see if the drug changes certain substances in urine, blood, and tissue that are associated with cancer development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A simple blood draw could spot colorectal cancer early
- Can a dental floss loop make polyp removal faster?
- AI eye on polyps: could a computer match the microscope?
- Can a new access tool make polyp removal faster and safer?
- Scientists map cellular secrets of recurring colon polyps to prevent future cancer